Independent Director · LIGAND PHARMACEUTICALS INC (LGND)

John L. LaMattina — LIGAND PHARMACEUTICALS Director Compensation (2025)

Fiscal year 2025 director compensation for John L. LaMattina at LIGAND PHARMACEUTICALS INC. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 21, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get John L. LaMattina’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track John L. LaMattina and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

LIGAND PHARMACEUTICALS Director Compensation Table · all 4 fiscal years held
In US dollars, as LIGAND PHARMACEUTICALS reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$49,539$128,142$262,888$0$440,569
FY2024$49,565$100,235$192,613—$342,413
FY2022$57,521$79,607$344,029—$481,157
FY2021$57,051$72,696$190,060—$319,807

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 21, 2026, accession 0000886163-26-000021, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LIGAND PHARMACEUTICALS INC filed document, accession 0000886163-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.

Get the LIGAND PHARMACEUTICALS Board Governance Report

$440,569 John L. LaMattina, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 21, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

LIGAND PHARMACEUTICALS pays directors a $42,000 cash retainer and $375,000 in RSUs and Options.

Committees

FY2025 · as the proxy prints them

Compensation · Human Capital · Science & Technology Operations

The rest of the LIGAND PHARMACEUTICALS board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Jason HaasIndependent Director$458,069
Jason M. AryehIndependent Director$450,569
John W. KozarichIndependent Director$473,069
Martine ZimmermannIndependent Director$444,185
Nancy R. GrayIndependent Director$448,069
Stephen L. SabbaIndependent Director$453,069
Todd C. DavisDirector—

The full LIGAND PHARMACEUTICALS compensation record

free company brief

This page is one director within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.

Peer companies

named in the LIGAND PHARMACEUTICALS proxy · each links to its own free brief

Order LGND

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report